

Special Issue

Cetuximab and Cancer

Message from the Guest Editors

The use of cetuximab in combination with chemotherapy represents a standard of care as first-line treatment for RAS wild-type metastatic colorectal cancer (CRC) and recurrent/metastatic head and neck cancer. More recently, the combination of cetuximab and the BRAF inhibitor encorafenib has been considered the best treatment option for pretreated BRAFV600E mutant colorectal cancer. Furthermore, new evidence suggests that rechallenge with cetuximab in combination with chemotherapy/immunotherapy could exert antitumor activity in pre-treated RAS wild-type colorectal cancer. To date, there are different matters of debate, including the optimization of available treatments, development of new combinatory strategies, identification of novel predictive biomarkers of response, and management of toxicities. In this Special Issue, original research articles and reviews regarding the role of cetuximab in cancer are welcome.

Guest Editors

Prof. Dr. Fortunato Ciardiello

Oncology Unit, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via S. Pansini 5, 80131 Naples, Italy

Dr. Davide Ciardiello

Oncology Unit, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via S. Pansini 5, 80131 Naples, Italy

Deadline for manuscript submissions

closed (1 August 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/130251

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)